drugset / Trial / NCT02344303

Study of the Effects of TRV130, at Therapeutic and Supra Therapeutic Doses, on QTc Intervals

NCT02344303

Phase 1 Completed 63 enrolled Trevena Inc.
RandomizedCrossoverTriple-blindTreatment

Summary

Assess the electrocardiogram effects of TRV130 relative to placebo at therapeutic and supratherapeutic doses.

Timeline

Start
2014-12
Primary completion
2015-05
Completion
2015-10

Drugs

EvaluationDrugModalityDoseRoute
Subject Moxifloxacin Small molecule
Subject Oliceridine Other / unclassified

Indications

No indication recorded.